The importance of limiting myocardial ischemia/reperfusion injury has been appreciated since Braunwald23,24 proposed that the extent and severity of tissue damage were not predetermined at the onset of ischemia, but could be modified by therapeutic manipulations applied during ischemia. Few years ago, a National Institutes of Health (NIH) expert’s panel concluded that cardioprotection is at a crossroads since approaches to identify cardioprotective therapies have been disappointing during the past 30 years.25 This may be related to the fact that the multiple candidates assayed so far target one single pathogenic event of the multiple damage cascade involved in myocardial damage and failure.25
The final verdict is to go for it. GHRP-6 is not your garden-variety performance enhancer. One of the most important aspects of it is that it does not cause desensitization. This means that it will not cause overdose and that works best for athletes. Also since it increases appetite, it forces you to make more calories available to your body for exercise and for recovery. It does not boost unnatural muscle growth like other performance enhancers and the result does not put extra pressure on your tendons and ligaments.
Specifically, T α 1 has been shown to enhance the function of certain immune cells called T and dendritic cells. This is very important to anyone with a depressed immune system or suffering from an infection, as these white blood cells play pivotal roles in the body’s defense process. T cells, for example, come in two forms: killer and helper T cells. Killer T cells are responsible for hunting down and destroying our body’s own cells that are cancerous or infected with bacteria or viruses. Helper cells work with the other cells of the immune system to orchestrate and carry out appropriate immune responses.
Before the discovery of ghrelin, synthetic GH secretagogs were available. Several studies investigated the effects of these substances on human sleep. Oral administration of the GH secretagog MK-677 for 1 week prompts a distinct sleep-promoting effect in healthy young male volunteers, whereas a weak effect is observed in elderly subjects. This study shows that oral administration of a peptide is capable of promoting sleep. After repetitive intravenous administration of GH-releasing peptide 6 (GHRP-6), non-REM sleep stage 2 increases. Similar to the effects of ghrelin in male subjects GH, ACTH, and cortisol are elevated. In a set of studies, the intranasal, oral, and sublingual administration of GHRP-6 was tested. By these routes of administration the effects of the peptide on the sleep EEG and on hormone secretion are less distinct and partly different from those after intravenous injection. In contrast to the sleep-promoting effects of GHRP-6 and ghrelin, hexarelin prompts a decrease of SWS, whereas the pattern of endocrine effects after hexarelin resemble the endocrine changes after ghrelin and GHRP-6 in that there is a marked stimulation of GH. The decrease of SWS after hexarelin may be related to negative feedback inhibition of endogenous GHRH. After a single dose of GHRP-2 during the third period of REM sleep, sleep remains unchanged. The lack of effects in this study may be related to the method that uses only a single injection of the substance.
Tβ4 has been used at our clinic with a great deal of success in patients suffering from Lyme disease or other infectious and/or inflammatory conditions. Tβ4 is very well tolerated and has not been found to cause any significant side effects. It can be taken on its own or in conjunction with an existing therapy, making it a versatile and valuable drug.